#Japan #Tokyo #Regenesome #Tokyo Institute #Space Seed

Regenesome's Certification: A New Milestone

Regenesome Inc., a subsidiary of Space Seed Holdings, has announced a significant achievement by receiving the 'Certified Venture' title from the Tokyo Institute of Science as of October 21, 2025. This designation is awarded to companies leveraging academic research outcomes to create social value, following a rigorous evaluation process by the university.

The certification, identified as title number 19, was officially bestowed by Yujiro Tanaka, the president of Tokyo Institute of Science. This accolade recognizes Regenesome’s potential in developing innovative solutions and societal contributions in the realm of longevity science.

Background of Regenesome

Founded on July 12, 2024, Regenesome is driven by a mission to utilize nanoparticles, such as exosomes, to develop cutting-edge solutions aimed at anti-aging and regenerative medicine. The company has positioned itself at the forefront of the longevity science field and is committed to forging ahead with research and business development efforts.

The establishment of the Takawa Longevity Lab in May 2025 has enhanced Regenesome's R&D capabilities. This facility serves as a headquarters and research institute, accelerating the company's innovative projects further. It is an ideal hub for advancing new healthcare solutions that leverage exosome technology while ensuring its practical applications in society.

Future Directions and Collaborations

The new certification is expected to catalyze further collaboration with the Tokyo Institute of Science in various pivotal areas, including:

• - Enhancing Aging Status Analysis Algorithms: Improving the precision and reliability of algorithms that analyze the aging processes in human cells and systems.
• - Developing Next-Generation Healthcare Solutions: Utilizing nanoparticles such as exosomes to create advanced healthcare products that address both preventative and curative measures in health management.
• - Research on Fermentation Technology Updates: Innovating fermentation techniques that align with recent scientific findings and technological advancements in the biological field.
• - New Product Development Utilization of Clinical, Data Science, and AI Technologies: Focusing on the creation of new products that incorporate artificial intelligence and data analytics, thereby transforming how healthcare solutions are developed.

As a certified university venture, Regenesome is poised to represent Japan on the global stage in the longevity science sector. The company aims to translate its research capabilities into concrete societal benefits, addressing critical issues regarding aging and health.

About Space Seed Holdings

Space Seed Holdings, the parent organization of Regenesome, operates with the mission to turn science fiction into reality. Their initiatives focus on investment, research, and business development in space-related deep-tech ventures. A core aspect of their operations includes the management of the 'Fermentation and Longevity Fund' program, which supports the societal implementation of fermentation and longevity technologies. By 2040, the organization aims to equip humanity with the necessary technologies to live sustainably in outer space.

In conclusion, Regenesome’s achievements and future projects signify an important shift not only in healthcare but also in how we understand and approach longevity science. Their commitment to innovation promises to bring transformative outcomes in extending healthy lifespans and exploring human habitation beyond Earth.

For more details about Regenesome, visit their official site: Regenesome.

To learn more about Space Seed Holdings, check out their website: Space Seed Holdings.